
The firm says purchasers of ADMA Biologics securities between Aug. 9, 2024 and March 25, 2026 may seek lead-plaintiff status in a case alleging undisclosed related-party dealings, channel stuffing and weak internal controls.
Purchasers of ADMA Biologics, Inc. securities between Aug. 9, 2024 and March 25, 2026 have until Aug. 10, 2026 to seek appointment as lead plaintiff in a securities class action, Rosen Law Firm said. The lawsuit alleges ADMA Biologics engaged in an undisclosed related party transaction, used channel stuffing to create an appearance of revenue, and lacked adequate internal controls. The complaint further claims those alleged issues meant defendants' statements about ADMA Biologics' business, operations and prospects were materially false and misleading or lacked a reasonable basis during the class period. Rosen said investors may participate under a contingency fee arrangement, and that investors do not need to serve as lead plaintiff to remain eligible for any potential recovery.